•  
  •  
 

Abstract

Background: Melasma is a common acquired pigmentary condition presenting as dark macules or patches on sun-exposed areas of the face. Conventional treatments rely on topical bleaching agents and sun protection, while additional adjuvant options such as chemical peels, dermabrasion, and laser procedures are often applied. However, recurrence is frequent, and overall therapeutic success remains modest, significantly affecting patient quality of life. Recently, tranexamic acid (TXA) has gained attention as a novel therapeutic approach. This review provides an overview of the available evidence on the efficacy of TXA, used as monotherapy or in combination regimens, for the management of melasma.

Discussion: TXA has been investigated for administration via several routes, including oral, intradermal, and topical. The pathophysiology of melasma involves not only abnormal melanogenesis but also enhanced dermal vascularity and angiogenic activity. TXA acts by interfering with the plasminogen–plasmin system, thereby altering keratinocyte–melanocyte signaling and reducing melanogenesis. In addition, it demonstrates anti-angiogenic effects, leading to reduced vessel density and erythema. Clinical data suggest oral TXA generally yields superior outcomes compared to intradermal or topical approaches, although study results remain heterogeneous, particularly in trials combining multiple therapies.

Conclusion: TXA appears to be a promising therapeutic option for melasma, with potential use as a stand-alone intervention or in combination with other modalities. Combination regimens often produce better clinical improvement than monotherapy. Nonetheless, standardized guidelines for the optimal use of TXA in melasma treatment remain lacking.

References

  1. Dawaud SMK, Hegab DS, El Maghraby GME, El-Ashmawy AA. Efficacy and safety of topical tranexamic acid alone or in combination with either fractional carbon dioxide laser or microneedling for the treatment of melasma. Dermatol Pract Concept. 2023;13(3):1–10.
  2. Calacattawi R, Alshahrani M, Aleid M, et al. Tranexamic acid as a therapeutic option for melasma management: Meta-analysis and systematic review of randomized controlled trials. J Dermatolog Treat. 2024;35(1):1–13.
  3. Kaikati J, El Bcherawi N, Khater JA, Dib SM, Kechichian E, Helou J. Combination topical tranexamic acid and vitamin C for the treatment of refractory melasma. J Clin Aesthet Dermatol. 2023;16(7):63–5.
  4. Majid I, Aleem S. Melasma: Update on epidemiology, clinical presentation, assessment, and scoring. J Skin Stem Cell. 2022;8(4):1–9.
  5. Yasnova N, Sirait SP, Rahmayunita G. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: A double-blind, split-face, randomized controlled trial. Acta Dermatovenerol Alp Pannonica Adriat. 2024;33(2):83–8.
  6. Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023;22(4):1197–206.
  7. Jiryis B, Toledano O, Avitan-Hersh E, Khamaysi Z. Management of melasma: Laser and other therapies-review study. J Clin Med. 2024;13(5):1–12.
  8. Gan C, Rodrigues M. An update on new and existing treatments for the management of melasma. Am J Clin Dermatol. 2024;25(5):717–33.
  9. Liu W, Chen Q, Xia Y. New mechanistic insights of melasma. Clin Cosmet Investig Dermatol. 2023;16:429–42.
  10. Grimes PE, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2018;5(1):30–6.
  11. Wang JV, Jhawar NS, Saedi N. Tranexamic acid for melasma: Evaluating the various formulations. J Clin Aesthet Dermatol. 2019;12(8):E73–4.
  12. Gaćina K, Ćosić AK. The use of tranexamic acid in dermatology. Acta Clin Croat. 2023;62(2):368–72.
  13. Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther (Heidelb). 2017;7(3):417–24.
  14. Chang YF, Lee TL, Oyerinde O, et al. Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis. J Cosmet Dermatol. 2023;22(4):1168–76.
  15. González-Molina V, Martí-Pineda A, González N. Topical treatments for melasma and their mechanism of action. J Clin Aesthet Dermatol. 2022;15(5):19–28.
  16. Goel A, Trivedi N. Current updates on melasma treatments. Cosmoderma. 2023;3(79):1–8.
  17. Lueangarun S, Sirithanabadeekul P, Wongwicharn P, et al. Intradermal tranexamic acid injection for the treatment of melasma: A pilot study with 48-week follow-up. J Clin Aesthet Dermatol. 2020;13(8):36–9.
  18. Sarkar R, Narayan RV, Vinay K, et al. Prescribing practices of tranexamic acid for melasma: Delphi consensus from the Pigmentary Disorders Society. Indian J Dermatol Venereol Leprol. 2024;90(1):41–5.
  19. Wang WJ, Wu TY, Tu YK, Kuo KL, Tsai CY, Chie WC. The optimal dose of oral tranexamic acid in melasma: A network meta-analysis. Indian J Dermatol Venereol Leprol. 2023;89(2):189–94.
  20. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):1–5.
  21. Godse K, Sarkar R, Mysore V, et al. Oral tranexamic acid for the treatment of melasma: Evidence-based consensus statement from Indian Experts. Indian J Dermatol. 2023;68(2):178–85.
  22. Panchal VS, Patel YS, Dalal YD, Parikh AP, Dalal AD, Rana DA. Efficacy of oral, topical, and intradermal tranexamic acid in patients with melasma—A meta-analysis. Indian Dermatol Online J. 2023;15(1):55–63.
  23. Del Rosario E, Florez-Pollack S, Zapata L Jr, et al. Randomized, placebo-controlled, double-blind study of tranexamic acid in the treatment of moderate to severe melasma. J Am Acad Dermatol. 2018;78(2):363–9.
  24. Heidary B, Meibodi GAH, Ardakani ME, Ramezani V, Heidari F. Randomized clinical trial on the efficacy of oral tranexamic acid versus topical tranexamic acid in treatment of melasma. J Cosmet Dermatol. 2025;24(9):1–5.
  25. Basit A, Rahman A, Uddin R. Oral tranexemic acid with triple combination cream (flucinolone+hydroquinone+tretinoin) versus triple combination cream alone in treatment of melasma. J Ayub Med Coll Abbottabad. 2021;33(2):293–8.
  26. Badran AY, Ali AU, Gomaa AS. Efficacy of topical versus intradermal injection of tranexamic acid in Egyptian melasma patients: A randomised clinical trial. Australas J Dermatol. 2021;62(3):e373–9.
  27. Poostiyan N, Alizadeh M, Shahmoradi Z, Naeini FF. Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor‐blind split‐face controlled trial. J Cosmet Dermatol. 2023;22(4):1238–44.
  28. Pazyar N, Molavi SN, Hosseinpour P, Hadibarhaghtalab M, Parvar SY, Dezfuly MB. Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: A split‐face comparative trial. Health Sci Rep. 2022;5(2):1–8.
  29. Raza MH, Iftikhar N, Anwar A, Mashhood AA, Tariq S, Bin Hamid MA. Split-face comparative analysis of micro-needling with tranexamic acid vs vitamin C serum in melasma. J Ayub Med Coll Abbottabad. 2022;34(1):169–72.
  30. Batra J, Brar BK, Kumar S, Arora H. Tranexamic acid in melasma: Comparative evaluation of therapeutic efficacy of oral tranexamic acid versus its transepidermal administration. J Cutan Aesthet Surg. 2022;15(4):394–9.
  31. Cassiano DP, Espósito ACC, Hassun KM, et al. Histological changes in facial melasma after treatment with triple combination cream with or without oral tranexamic acid and/or microneedling: A randomised clinical trial. Indian J Dermatol Venereol Leprol. 2022;88(6):761–70.
  32. Mawu FO, Kapantow MG, Pandaleke HEJ, et al. Comparative efficacy of topical 10% versus 5% tranexamic acid in treatment of women with melasma: A double-blind randomized controlled trial. Universa Medicina. 2024;43(2):213–9.
  33. Maeda K. Mechanism of action of topical tranexamic acid in the treatment of melasma and sun-induced skin hyperpigmentation. Cosmetics. 2022;9(5):1–13.
  34. Guo L, Liu X, Liu Q, Xie X, Jiang X. Treatment of melasma with tranexamic acid essence combined with iontophoresis: A randomized, double-blind, placebo-controlled clinical trial. Drug Des Devel Ther. 2024;18:3659–66.
  35. Rahimnia A, Hosnian M, Ehsani A, et al. Efficacy of non-ablative fractional laser combined with tranexamic acid in melasma treatment: A randomized split-face trial. J Cosmet Dermatol. 2025;24(8):1–9.

Download

Share

COinS